RU2015115520A - Recombinant vaccine for the prevention of viral hepatitis B (Options) - Google Patents
Recombinant vaccine for the prevention of viral hepatitis B (Options) Download PDFInfo
- Publication number
- RU2015115520A RU2015115520A RU2015115520A RU2015115520A RU2015115520A RU 2015115520 A RU2015115520 A RU 2015115520A RU 2015115520 A RU2015115520 A RU 2015115520A RU 2015115520 A RU2015115520 A RU 2015115520A RU 2015115520 A RU2015115520 A RU 2015115520A
- Authority
- RU
- Russia
- Prior art keywords
- hepatitis
- kbt
- polymorpha
- virus
- recombinant vaccine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/16—Yeasts; Culture media therefor
- C12N1/18—Baker's yeast; Brewer's yeast
Abstract
1. Рекомбинантная вакцина для профилактики вирусного гепатита В, содержащая эффективное количество поверхностного антигена вируса гепатита, адъювант и физиологически приемлемый разбавитель, отличающаяся тем, что в качестве антигена вируса гепатита В рекомбинантная вакцина содержит в равных долях смесь поверхностного антигена вируса гепатита В, имеющего мутацию G145R (ESC-Ag), полученного путем культивирования рекомбинантного штамма дрожжей Н. Polymorpha КБТ-11/ pEMmulti-7 или Н. Polymorpha КБТ-12/pEMmono-4, или Н. Polymorpha КБТ-14/pEMmalt-8, или Н. Polymorpha КБТ-14/рЕМmono2, и HBsAg серотипа ayw и/или HBsAg серотипа adw.2. Рекомбинантная вакцина для профилактики вирусного гепатита В по п. 1, отличающаяся тем, что дополнительно содержит мертиолят.3. Рекомбинантная вакцина для профилактики вирусного гепатита В, содержащая эффективное количество поверхностного антигена вируса гепатита, адъювант и физиологически приемлемый разбавитель, отличающаяся тем, что в качестве антигена вируса гепатита В рекомбинантная вакцина содержит поверхностный антиген вируса гепатита В, имеющий мутацию G145R (ESC-Ag), полученный путем культивирования рекомбинантного штамма дрожжей Н. Polymorpha КБТ-11/pEMmulti-7 или Н. Polymorpha КБТ-12/pEMmono-4, или Н. Polymorpha КБТ-14/ pEMmalt-8, или Н. Polymorpha КБТ-14/рЕМmono2.4. Рекомбинантная вакцина для профилактики вирусного гепатита В по п. 1, отличающаяся тем, что дополнительно содержит мертиолят.1. Recombinant vaccine for the prevention of viral hepatitis B, containing an effective amount of a surface antigen of hepatitis B virus, an adjuvant and a physiologically acceptable diluent, characterized in that as a hepatitis B virus antigen, the recombinant vaccine contains in equal proportions a mixture of hepatitis B virus surface antigen having a G145R mutation (ESC-Ag) obtained by culturing a recombinant yeast strain of N. Polymorpha KBT-11 / pEMmulti-7 or N. Polymorpha KBT-12 / pEMmono-4, or N. Polymorpha KBT-14 / pEMmalt-8, or N. Polymorpha KBT-14 / pEMmono2, and HBsAg Ser ayw type and / or serotype HBsAg adw.2. A recombinant vaccine for the prevention of viral hepatitis B according to claim 1, characterized in that it additionally contains merthiolate. 3. A recombinant vaccine for the prevention of viral hepatitis B containing an effective amount of a surface antigen of hepatitis B virus, an adjuvant and a physiologically acceptable diluent, characterized in that, as an antigen of hepatitis B virus, a recombinant vaccine contains a surface antigen of hepatitis B virus having a G145R mutation (ESC-Ag), obtained by culturing a recombinant yeast strain of N. Polymorpha KBT-11 / pEMmulti-7 or N. Polymorpha KBT-12 / pEMmono-4, or N. Polymorpha KBT-14 / pEMmalt-8, or N. Polymorpha KBT-14 / pEMmono2. four. Recombinant vaccine for the prevention of viral hepatitis B according to claim 1, characterized in that it additionally contains merthiolate.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2015115520/10A RU2603729C2 (en) | 2015-04-24 | 2015-04-24 | Recombinant vaccine for prophylaxis of hepatitis b (versions) |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2015115520/10A RU2603729C2 (en) | 2015-04-24 | 2015-04-24 | Recombinant vaccine for prophylaxis of hepatitis b (versions) |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2015115520A true RU2015115520A (en) | 2016-11-20 |
RU2603729C2 RU2603729C2 (en) | 2016-11-27 |
Family
ID=57759496
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2015115520/10A RU2603729C2 (en) | 2015-04-24 | 2015-04-24 | Recombinant vaccine for prophylaxis of hepatitis b (versions) |
Country Status (1)
Country | Link |
---|---|
RU (1) | RU2603729C2 (en) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9007024D0 (en) * | 1990-03-29 | 1990-05-30 | Imperial College | Novel vaccine |
US5639637A (en) * | 1990-03-29 | 1997-06-17 | Imperial College Of Science, Technology & Medicine | Hepatitis B vaccine |
AU756858B2 (en) * | 1998-06-19 | 2003-01-23 | Government Of The Republic Of Singapore | A vaccine-induced hepatitis B viral strain and uses thereof |
RU2238105C1 (en) * | 2003-03-14 | 2004-10-20 | Закрытое акционерное общество научно-производственная компания "Комбиотех" | Recombinant vaccine for preventing viral hepatitis b (variants) |
-
2015
- 2015-04-24 RU RU2015115520/10A patent/RU2603729C2/en active
Also Published As
Publication number | Publication date |
---|---|
RU2603729C2 (en) | 2016-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018500199A1 (en) | Antibodies that potently neutralize hepatitis b virus and uses thereof | |
MX340880B (en) | Improved vaccines and methods for using the same. | |
EA201891415A8 (en) | HUMAN IMMUNODEFICIENCY VIRUS ANTIGENS, VECTORS, COMPOSITIONS AND WAYS OF THEIR APPLICATION | |
EA202091513A1 (en) | VACCINES AGAINST HEPATITIS B VIRUS (HBV) AND THEIR APPLICATION | |
EP3266464A3 (en) | Yeast-based therapeutic for chronic hepatitis b infection | |
RU2015132962A (en) | IMMUNOGENIC COMPOSITIONS BASED ON INFLUENZA VIRUS AND THEIR APPLICATION | |
ATE527281T1 (en) | VACCINES AGAINST AIDS COMPRISING CMV/R NUCLEIC ACID CONSTRUCTS | |
JP2016155867A5 (en) | ||
MX2016004063A (en) | Pcv2 orf2 protein variant and virus like particles composed thereof. | |
WO2015142671A3 (en) | Influenza virus vectors and uses therefor | |
WO2015195218A8 (en) | Polyvalent influenza virus-like particles (vlps) and use as vaccines | |
PH12020550924A1 (en) | Heptatitis b virus (hbv) vaccines and uses thereof | |
EA201892735A1 (en) | COMPOSITION OF VACCINE AGAINST HIV | |
ZA202104213B (en) | Antibodies that neutralize hepatitis b virus and uses thereof | |
EA202091516A1 (en) | METHODS AND COMPOSITIONS FOR INDUCING IMMUNE RESPONSE AGAINST HEPATITIS B VIRUS (HBV) | |
WO2014150822A3 (en) | Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use | |
HRP20240163T1 (en) | Methods and compositions for inducing protective immunity against filovirus infection | |
CA2839668C (en) | Epitope and its use of hepatitis b virus surface antigen | |
PH12018502436A1 (en) | Multivalent vaccines major swine viral diseases | |
EA201790365A1 (en) | HUMAN PAPILLOMA VIRUS ANTIGENES WITH GOOD IMMUNOLOGICAL PROPERTIES AND CONTAINING THEIR VACCINE | |
WO2018066999A3 (en) | Chimeric enterovirus virus-like particles | |
AU2017261706A1 (en) | Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process | |
EA201892179A1 (en) | VACCINE FOR TREATING HEPATITIS B ON THE BASIS OF INACTIVATED WHOLE RECOMBINANT CELLS HANSENULA POLYMORPHA, WHICH EXPRESS HBsAg | |
MX2019007924A (en) | Influenza vaccines. | |
RU2015115520A (en) | Recombinant vaccine for the prevention of viral hepatitis B (Options) |